Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)-Reference-Cited by-同舟云学术

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Published:2013-04 Issue:4 Volume:24 Page:1011-1017
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bamias A.,Dafni U.,Karadimou A.,Timotheadou E.,Aravantinos G.,Psyrri A.,Xanthakis I.,Tsiatas M.,Koutoulidis V.,Constantinidis C.,Hatzimouratidis C.,Samantas E.,Visvikis A.,Chrisophos M.,Stravodimos K.,Deliveliotis C.,Eleftheraki A.,Pectasides D.,Fountzilas G.,Dimopoulos M.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/4/1011/13788968/mds583.pdf

Reference26 articles.

1. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s;Karim-Kos;Eur J Cancer,2008

2. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium;Sternberg;J Urol,1985

3. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium;Sternberg;J Urol,1988

4. Advanced bladder cancer: The need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world;Roth;J Urol,1995

5. Long-term follow-up of a phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Saxman;J Clin Oncol,1997

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer;International Journal of Urology;2024-07-03

2. The evolving treatment landscape of metastatic urothelial cancer;Nature Reviews Urology;2024-05-03

3. Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale;Journal of Chemotherapy;2024-04-17

4. Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion;Clinical Genitourinary Cancer;2024-04

5. Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma;World Journal of Urology;2024-01-10